Study S000138

Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04575844
Acronym: ZQL008
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: RECRUITING
Enrollment: 80
Start: 2020-11-01
Primary completion: 2027-04-30
Lead sponsor: University of Virginia
Conditions: Metabolic Syndrome
Interventions: DRUG:Liraglutide; OTHER:Exercise training; DRUG:Liraglutide + Exercise training
Results posted: FALSE
Secondary identifiers: NIH:R01DK125330

Registered primary outcomes

Microvascular Blood Volume - change from baseline [24 weeks]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0025781	3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. le Roux CW, Lancet (London, England)	2017	Randomized trial	PMID 28237263 DOI	registry reference BACKGROUND:28237263
R0022060	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. Marso SP, The New England journal of medicine	2016	Randomized trial	PMID 27295427 DOI	registry reference BACKGROUND:27295427
R0030559	Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Basu A, American journal of physiology. Endocrinology and metabolism	2007	Randomized trial	PMID 17711996 DOI	registry reference BACKGROUND:17711996